TG Therapeutics (TGTX) Misses Q1 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/9/2026
- Nasdaq ends sharply higher; chip surge offsets Iran worries
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Applied Materials surges as CEO signals multi-year chip boom
- Oil prices settle 2% lower as economic worries outweigh supply risks
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- GameStop stockholders approve share count increase to 2.5 billion
- Crude Inventory Rose 3 Million Barrels Last Week - EIA
- AI bubble fears mount as Zuckerberg admits agent delays and Burry shorts sector
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
TG Therapeutics, Inc. Announces First Quarter 2015 Financial Results and Business Update
May 4, 2015 5:01 PM EDTNEW YORK, May 4, 2015 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (Nasdaq: TGTX) today announced its financial results for the first quarter ended March 31, 2015 and recent company developments.
Michael S. Weiss, the Company's Executive Chairman and Interim Chief Executive Officer, stated, "During the first quarter, we focused on site initiation and enrollment into our GENUINE Phase 3 clinical trial, as well as the continued enrollment into our Phase 1/2 trial of our proprietary combination of TG-1101 and TGR-1202, also referred to as 1303, and we look forward to presenting updated data from these studies next month.... More
